Immersive Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis

Launched by GLASGOW CALEDONIAN UNIVERSITY · Apr 1, 2022

Keywords

ClinConnect Summary

The aim of this study is to investigate the feasibility of an eight-week intervention of co-produced virtual reality (VR) games delivered using the Oculus Quest for improving the upper limb function of people with MS. This study is also a randomised controlled trial with two arms, one group will undergo the intervention using VR and the other will be a control group.

This study aims to recruit up to 30 people with MS who have some degree of self-reported upper limb mobility difficulties from MS clinics in NHS Lanarkshire and MS Revive, a third sector in Glasgow. Participants will be random...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed diagnosis of multiple sclerosis.
• • Degree of self-reported hand or upper limb impairment which interferes with some activities of daily living (ADL) (e.g. dressing, eating, grooming).
• • Objective upper limb impairment, in at least one hand, as determined by a Nine Hole Peg Test (see Section Outcome Measures) of 2 standard deviations of more above the published normative values depending on age and sex.
• • Must be able to travel to a research site.
• Exclusion Criteria:
• • If they have had a relapse in the last three months
• • Subjective cognitive problems resulting in them being unable to use the equipment or participate in virtual reality.
• • Visual problems such that they cannot see the visual display within the headset (this does not include participants who have glasses that are enough to correct eyesight issues)
• • Have a current eye infection.
• • Have any significant co-existing neurological or orthopaedic conditions affecting the upper limb.
• • Are unable to understand verbal or written explanations of the study or are unable to speak or understand English.
• • Individuals who are currently enrolled in any clinical trials will be excluded, but those who have previously taken part in research and other trials will be eligible.